Ipsen, Vernalis deal

Vernalis received $1.9 million as the final milestone payment from Ipsen under a 2008 deal in which Ipsen acquired Vernalis' U.S. commercial operations subsidiary and U.S. rights to Vernalis' Apokyn apomorphine. The payment brings the total amount of milestones received from the deal to $3.6 million. Under the terms of the 2008 deal, the final milestone payment was to be triggered by combined net annual sales of Apokyn and Ipsen's Dysport abobotulinumtoxinA that exceeded $50 million. Dysport is marketed in the U.S. through the subsidiary to treat cervical dystonia (see BioCentury, July 7, 2008). ...